Dysbiosis of the Gut Microbiome Is Associated With Histopathology of Lung Cancer.
Dysbiosis of the Gut Microbiome Is Associated With Histopathology of Lung Cancer.
复制标题
DOI：
10.3389/fmicb.2022.918823
复制
发表时间：
2022
影响因子：
5.2
通讯作者：
Jiao, Lijing
中科院分区：
文献类型：
--
作者：
Qin, Xiong;Bi, Ling;Yang, Wenxiao;He, Yiyun;Gu, Yifeng;Yang, Yong;Gong, Yabin;Wang, Yichao;Yan, Xiaoxia;Xu, Ling;Xiao, Haibo;Jiao, Lijing
肺癌是世界范围内发病率高、死亡率高的恶性肿瘤。先前的研究表明，肠道微生物组在代谢性癌症的发生和发展中起着重要作用。然而，关于不同组织病理类型肺癌的肠道微生物组特征的数据仍然很少。我们收集了28名健康人（HP）和61名肺癌患者的粪便样本。肺癌患者根据其组织病理学分为非典型腺瘤性增生/原位腺癌（AAH/AIS）、微创腺癌（MIA）和浸润性腺癌（IA）三种类型。此外，我们采用16S rRNA基因扩增子测序来分析这些患者肠道微生物组的特征。我们的分析显示，分类癌症患者具有独特的肠道菌群特征，与健康人群相比，其密度和菌群多样性较低。此外，菌群科属结构更为复杂，每一组都有特定的致病菌群。与IA和MIA组相比，AAH/AIS组和HP组患者的菌群结构相对相似。此外，我们还发现了一些随着肺癌发展而发生显著变化的菌群标记物。与健康人群相比，肺癌患者肠道微生物群中产生短链脂肪酸（SCFAs）和抗炎细菌的数量减少，而一些致病菌，如促炎或促肿瘤细菌，在肺癌患者中更为丰富。另一方面，京都基因与基因组百科全书（KEGG）和同源群簇（COG）注释显示，肺癌中一些显性代谢相关途径受到抑制。这些发现为肺癌的诊断和预后评估提供了新的生物标志物，为肺癌的预防和治疗提供了新的靶向治疗策略基础。[www.ClinicalTrials.gov]，标识符[NCT03244605]。
Lung cancer is a malignancy with high incidence and mortality worldwide. Previous studies have shown that the gut microbiome plays an important role in the development and progression of metabolic cancers. However, data on the characteristics of the gut microbiome with different histopathology types of lung cancer remain scant. We collected stool samples from 28 healthy people (HP) and 61 lung cancer patients. The lung cancer patients were classified into three types according to their histopathology: Atypical Adenomatous Hyperplasia/Adenocarcinoma in situ (AAH/AIS), Minimally Invasive Adenocarcinoma (MIA), and Invasive Adenocarcinoma (IA). In addition, we employed 16S rRNA gene amplicon sequencing to analyze the characteristics of the gut microbiome in these patients. Our analysis revealed that the categorized cancer patients had unique intestinal flora characteristics, and had lower density and flora diversity compared to healthy people. Besides, the structure of the flora families and genera was more complex, and each group presented specific pathogenic microbiota. The patients in the AAH/AIS group and HP group had relatively similar flora structure compared with the IA and MIA groups. In addition, we identified several flora markers that showed significant changes with the development of lung cancer. Lung cancer gut microbiota showed a decrease in short-chain fatty acids (SCFAs) producing and anti-inflammatory bacteria compared to healthy people, while some pathogenic bacteria such as proinflammatory or tumor-promoting bacteria were more abundant in lung cancer patients. On the other hand, the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Clusters of Orthologous Group (COG) annotation demonstrated suppression of some dominant metabolism-related pathways in lung cancer. These findings provide new biomarkers for the diagnosis and prognostic assessment of lung cancer and lay the basis for novel targeted therapeutic strategies for the prevention and treatment of lung cancer. [www.ClinicalTrials.gov], identifier [NCT03244605].
登录
查看更多内容
DOI：
10.1038/nrmicro3552
发表时间：
2016-01
期刊：
Nature reviews. Microbiology
影响因子：
--
作者：
Donaldson GP;Lee SM;Mazmanian SK
通讯作者：
Mazmanian SK
影响因子：
64.8
作者：
通讯作者：
--
影响因子：
14.9
作者：
Kanehisa M;Araki M;Goto S;Hattori M;Hirakawa M;Itoh M;Katayama T;Kawashima S;Okuda S;Tokimatsu T;Yamanishi Y
通讯作者：
Yamanishi Y
肠道微生物群：健康和疾病的整体调节因素
影响因子：
5.2
作者：
Feng Q;Chen WD;Wang YD
通讯作者：
Wang YD
影响因子：
6.4
作者：
Daniel, Scott G.;Ball, Corbie L.;Hurwitz, Bonnie L.
通讯作者：
Hurwitz, Bonnie L.